echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 100% cure rate with avekira Pak

    100% cure rate with avekira Pak

    • Last Update: 2015-06-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley 2015-6-26 at present, in the field of hepatitis C treatment, two giants, Gilead and abbvie, which have successively launched their own new generation of all oral hepatitis C cocktails, are engaged in fierce confrontation However, from the current situation, Aberdeen is obviously in the downwind, because there are data showing that Geely's share of the hepatitis C treatment market has reached 85% How to obtain and maintain more market share is a difficult problem for abway However, the powerful data on the efficacy of the hepatitis C cocktail viekira Pak in the treatment of hepatitis C subtype group released by Aberdeen recently is expected to help the company achieve a breakthrough in the niche market (i.e niche market) This is the data of a phase IIIB clinical study (turquoise-iii), which was carried out in 60 adult patients with genotype 1b (gt1b) chronic hepatitis C virus (HCV) with compensatory cirrhosis The data showed that patients achieved 100% (n = 60 / 60) sustained virological response (svr12) after 12 weeks of treatment with viekira Pak ) Relevant data will be submitted to the 15th International Forum on viral hepatitis and liver disease (isvhld), held in Berlin, Germany, from June 26 to 28 This data will help albove to further expand its hepatitis C business; and the study of turquoise-iii itself also reflects the development strategy that albove strives to achieve a breakthrough in the hepatitis C subtype group - to create a "niche" market and highlight the advantages of its own drugs At present, the company is carrying out a large-scale phase IIIB project to evaluate the clinical benefits of the hepatitis C cocktail viekira Pak in different types of hepatitis C groups The study of turquoise-iii is one of the studies of phase IIIB project It is estimated that there are about 160 million patients with hepatitis C worldwide, of which genotype 1 (GT1) is the most common subtype of hepatitis C, accounting for about 60% In Europe, genotype 1b (gt1b) is the most common, accounting for about 47% Over time, chronic hepatitis C can cause liver complications, including cirrhosis, in about 10-20% of patients About the niche market, niche market refers to some market segments that are usually ignored by large enterprises in the market, which is used to describe the niche market in the large market Niche strategy refers to the competitive strategy adopted by enterprises to occupy these markets through specialized operation according to their own unique resource advantages, so as to maximize the income, that is, to select a subdivided consumer group to obtain the maximum marginal income About the study of turquoise-iii: turquoise-iii is a multicenter, open label phase IIIB study It was carried out in 60 adult patients with hepatitis C of genotype 1b with compensatory cirrhosis who were initially treated or treated (pegylated interferon + ribavirin treatment failure) The cocktail of hepatitis C, viekira Pak (viekirax + xviera), was evaluated , no ribavirin) for 12 weeks The primary end point was the proportion of patients who achieved sustained virological response (svr12) Data showed that after 12 weeks of treatment with viekira Pak (no ribavirin), all patients (100%, n = 60 / 60) achieved svr12 and reached the main end point of the study In the study, there was no drug withdrawal due to adverse reactions, no virological failure in the treatment process, and no virological recurrence after the treatment The most common adverse events (> 10%) were fatigue (22%), diarrhea (20%) and headache (18%).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.